(Dana-Farber Cancer Institute) Dana-Farber Cancer Institute and the Sanford-Burnham Medical Research Institute have signed a license agreement with Genentech, a wholly owned member of the Roche group, and Roche, that grants the companies exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses. These viruses include the strains for the current seasonal and H1N1 influenzas.

Further information:

Article source

Related posts:

1. Delaying post-surgical radiation increases risk of breast cancer recurrence in older women
2. African-Americans’ attitudes about lung cancer may hinder prevention
3. Sanford-Burnham scientists identify natural compound that inhibits cancer cell migration
4. Questions & Answers about the 2009-2010 Flu Season
5. Questions & Answers about the 2009–2010 Flu Season